C
Charles M. Perou
Researcher at University of North Carolina at Chapel Hill
Publications - 645
Citations - 235604
Charles M. Perou is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 156, co-authored 573 publications receiving 202951 citations. Previous affiliations of Charles M. Perou include North Carolina Central University & University of Chicago.
Papers
More filters
Journal ArticleDOI
Epidemiology of basal-like breast cancer (Breast Cancer Research and Treatment DOI: 10.1007/s10549-007-9632-6)
Journal ArticleDOI
Microarrays and epidemiology: ensuring the impact and accessibility of research findings.
TL;DR: Gene expression microarrays have contributed to important discoveries in cancer biology in the past decade and, in some cases, have permanently altered the authors' concepts of the disease.
Journal ArticleDOI
Correction: Alterations in Wnt- and/or STAT3 signaling pathways and the immune microenvironment during metastatic progression.
TL;DR: These studies illustrate the importance of analyzing intratumoral heterogeneity, changes in population dynamics, and the immune microenvironment during metastatic progression, as well as revealing a significant association with immune response signatures.
Journal ArticleDOI
Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features.
Halei C. Benefield,Katherine E. Reeder-Hayes,Hazel B. Nichols,Benjamin C. Calhoun,Michael I. Love,Erin L. Kirk,Joseph Geradts,Katherine A. Hoadley,Stephen R. Cole,H. Shelton Earp,Andrew F. Olshan,Lisa A. Carey,Charles M. Perou,Melissa A. Troester +13 more
TL;DR: Differences in recurrence by race appear greatest among women with aggressive tumors and may be influenced by treatment differences.
Patent
Methods of treating breast cancer with anthracycline therapy
TL;DR: In this article, the authors describe methods for screening subjects with breast cancer to determine if the breast cancer will be responsive to a breast cancer therapy including an anthracycline, and also describes methods for treating subjects with cancer by screening them for the likelihood of the effectiveness of treating the cancer with a therapy.